"Synopsys has whipsawed investors. The stock collapsed to $389.83 by November 2025 after a brutal Q3 FY25 miss, then clawed back to $510.02. Year to date, shares are up 8.58%, with the one-month surge of 21.78% reflecting renewed confidence in the Ansys story. The 52-week range runs from $376.18 to $651.73."
"Q1 FY26, reported February 25, delivered revenue of $2.41 billion (up 65.4% YoY) and non-GAAP EPS of $3.77 against a $3.55 consensus, a 5.98% beat. Operating cash flow swung to $856.83 million from negative $67 million a year earlier, and management paid down $3.45 billion in long-term debt during the quarter."
"The bull case rests on FY26 guidance of revenue between $9.56 billion and $9.66 billion and non-GAAP EPS of $14.38 to $14.46, including roughly $2.9 billion in Ansys revenue. CEO Sassine Ghazi said Synopsys has "the most compelling roadmap in our history" as AI fuels chip design R&D. The Ansys deal expanded the addressable market by 63% to $31 billion."
"The bear case starts with valuation. Trailing P/E sits at 78, with forward P/E at 36. China accounts for roughly 10% of revenue and remains exposed to U.S. export controls. Morgan Stanley flagged gr"
Synopsys shares rose 21.78% over the past month after a late-2025 decline. The stock fell to $389.83 by November 2025 following a Q3 FY25 miss, then recovered to $510.02. Q1 FY26 results reported February 25 showed revenue of $2.41 billion, up 65.4% year over year, and non-GAAP EPS of $3.77 versus $3.55 consensus. Operating cash flow increased to $856.83 million from negative $67 million a year earlier, and management paid down $3.45 billion in long-term debt. FY26 guidance calls for revenue between $9.56 billion and $9.66 billion and non-GAAP EPS between $14.38 and $14.46, including about $2.9 billion from Ansys. The Ansys deal expanded the addressable market by 63% to $31 billion, while risks include high valuation, China exposure, and U.S. export controls.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]